Overcoming Drug Resistance to BRAF Inhibitor.
Overcoming Drug Resistance to BRAF Inhibitor.
Bull Math Biol. 2020 Jan 14;82(1):8
Authors: Friedman A, Siewe N
Abstract
One of the most frequently found mutations in human melanomas is in the B-raf gene, making its protein BRAF a key target for therapy. However, in patients treated with BRAF inhibitor (BRAFi), although the response is very good at first, relapse occurs within 6 months, on the average. In order to overcome this drug resistance to BRAFi, various combinations of BRAFi with other drugs have been explored, and some are being applied clinically, such as a combination of BRAF and MEK inhibitors. Experimental data for melanoma in mice show that under continuous treatment with BRAFi, the pro-cancer MDSCs and chemokine CCL2 initially decrease but eventually increase to above their original level, while the anticancer T cells continuously decrease. In this paper, we develop a mathematical model that explains these experimental results. The model is used to explore the efficacy of combinations of BRAFi with anti-CCL2, anti-PD-1 and anti-CTLA-4, with the aim of eliminating or reducing drug resistance to BRAFi.
PMID: 31933021 [PubMed - in process]
Source: Bulletin of Mathematical Biology - Category: Bioinformatics Authors: Friedman A, Siewe N Tags: Bull Math Biol Source Type: research
More News: Bioinformatics | Biology | Cancer | Cancer & Oncology | Genetics | Melanoma | Skin Cancer